In their research, the academics emphasized that a detected signal of semaglutide-associated suicidal ideation compels urgent clarification, underscoring the need to scrutinize reported adverse reactions.
Their analysis revealed a concerning 45% increase in reports of suicidal thoughts linked to semaglutide compared to other medications, although these reports were relatively rare at just 0.35%.
Interestingly, researchers in January 2024 indicated that semaglutide users had a lower risk of suicidal ideation than those on non-GLP-1 receptor agonists, contradicting earlier findings.
The EMA and FDA concluded that the evidence does not establish a direct link between GLP-1 receptor agonists like semaglutide and suicidal thoughts, but further investigation is warranted.
Collection
[
|
...
]